Bay Area PKPD Network Special Topics Webinar
Thursday, June 10, 2021 from 12:00pm-1:00pm PDT Location: Online Register: for free at https://tinyurl.com/BAPKPD-webinar2021 or see http://www.bapkpd.org/upevent.html for information Kathy Giacomini, Ph.D. Professor, Department of Bioengineering and Therapeutic Sciences UCSF Schools of Pharmacy and Medicine High Throughput Screening and Real World Biomarkers to Predict Drug-Drug and Drug-Nutrient Interactions: Implications to polypharmacy associated with COVID treatment Individuals with serious COVID infections often have pre-existing co-morbidities and are generally older. Thus, in addition to being prescribed drugs for the treatment of COVID19 and its sequelae, many of these individuals are taking a myriad of other drugs. In this presentation, I will describe a screening study of 25 small molecule drugs in clinical trials for COVID19 against 11 drug transporters, which are targets for clinically relevant drug-drug interactions (DDIs). Our in vitro studies revealed that 20 of the 25 drugs met the criteria suggested by FDA DDI guidance to consider a clinical DDI study. Further, I will describe the analyses of real world transporter biomarkers in data from electronic health records, which suggested that several of the drugs actually do cause transporter-mediated DDIs clinically. I will end with a discussion of the propensity for many anti-microbial drugs to perpetrate clinical DDIs and drug-nutrient interactions, and the use of various biomarkers for predicting DDIs in pre- and post-marketing settings.
